Adolescent depression: A placebo-controlled fluoxetine treatment study and follow-up

  title={Adolescent depression: A placebo-controlled fluoxetine treatment study and follow-up},
  author={Jovan G. Simeon and Vincenzo F. Dinicola and H. Bruce Ferguson and Warren Copping},
  journal={Progress in Neuro-Psychopharmacology and Biological Psychiatry},

Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial.

Fluoxetine 20 mg daily appears to be well tolerated and effective for acute treatment of MDD in child and adolescent outpatients.

A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression.

Fluoxetine was superior to placebo in the acute phase treatment of major depressive disorder in child and adolescent outpatients with severe, persistent depression, and complete remission of symptoms was rare.

Treatment of elective mutism with fluoxetine: a double-blind, placebo-controlled study.

  • B. BlackT. Uhde
  • Medicine, Psychology
    Journal of the American Academy of Child and Adolescent Psychiatry
  • 1994
Fluoxetine may be beneficial and safe in the treatment of children with elective mutism and longer periods of treatment may yield more substantial therapeutic benefits.

Long-term sertraline treatment of children and adolescents with major depressive disorder.

Sertraline appears to be well tolerated and safe over 24 weeks of treatment in children and adolescents with MDD, with patients showing continued improvement in CDRS-R scores regardless of which treatment they received in the double-blind studies.

Rapid response to psychosocial treatment for adolescent depression: a two-year follow-up.

These findings suggest that milder forms of depression may benefit from initial supportive therapy or short trials of more specialized types of psychotherapy, and the use of a placebo run-in period might help to "wash out" nonspecific responders.

Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder.

The results suggest that fluoxetine is a generally safe and effective short-term treatment for children with OCD.

The Treatment for Adolescents With Depression Study (TADS): demographic and clinical characteristics.

The Treatment for Adolescents With Depression Study provides a large, diverse, and representative sample of depressed adolescents that highlights the complexity of major depressive disorder in adolescents and provides a rich source for explicating the effects of moderator and mediator variables on baseline psychopathology and treatment outcome.

Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial.

Paroxetine demonstrated significantly greater improvement compared with placebo in Hamilton Rating Scale for Depression total score < or = 8, HAM-D depressed mood item, K-SADS-L depressed Mood item, and CGI score of 1 or 2.

Mirtazapine in the Treatment of Adolescents with Major Depression: An Open-Label, Multicenter Pilot Study

It is suggested that mirtazapine may be an effective treatment for major depression in adolescents and showed a marked efficacy on all rating scales and was well tolerated.

Adolescent depression: Controlled desipramine treatment and atypical features

A relatively high rate of atypical depression was observed, suggesting the need for very large samples to detect differential treatment efficacy, should it exist in adolescents with major depression, and may have relevance to future investigation of therapeutic interventions in adolescent MDD.



Fluoxetine versus trazodone in the treatment of outpatients with major depression.

Fluoxetine and trazodone were compared in a double-blind, randomized, parallel, 6-week trial in 43 outpatients with major depression after a 1-week single-blind placebo period. Thirty-five patients

A fixed-dose clinical trial of fluoxetine in outpatients with major depression.

The 20-mg dose produced improvement of depression in the moderate-severe depression group as expressed in significant reductions of scores on the Hamilton Rating Scale for Depression and the Patient Global Impressions scale.

A review of multicenter controlled studies of fluoxetine vs. imipramine and placebo in outpatients with major depressive disorder.

Fluoxetine had significantly less associated anticholinergic effects, dizziness, drowsiness, somatosensory disturbance, and excessive sweating than imipramine, and although nausea occurred more frequently in fluoxettine patients, it was generally mild and well tolerated.

Depressive disorders in children and adolescents.

  • Sim Jg
  • Psychology, Medicine
  • 1989
Open drug studies suggest that antidepressants are useful in depressed children andPolysomnographic findings in childhood depression appear unremarkable and in adolescent depression these findings are similar to those in depressed adults.

Impact of severity and chronicity of parental affective illness on adaptive functioning and psychopathology in children.

Almost every measure of severity and chronicity of depression in the biological parents has a statistically significant association with currently impaired adaptation and the presence of a DSM-III-diagnosed disorder in the children, as do the measures of increased discord among married or separated parents.

The Hopkins Symptom Checklist (HSCL): a self-report symptom inventory.

The historical evolution, development, rationale and validation of the Hopkins Symptom Checklist is described, a self-report symptom inventory comprised of 58 items which are representative of the symptom configurations commonly observed among outpatients.

Development of a rating scale for primary depressive illness.

  • M. Hamilton
  • Psychology
    The British journal of social and clinical psychology
  • 1967
This is an account of further work on a rating scale for depressive states, including a detailed discussion on the general problems of comparing successive samples from a ‘population’, the meaning of